GT200800256A - Derivados de pirazolo [3,4-d]-pirimidina útiles para tratar trastornos respiratorios - Google Patents

Derivados de pirazolo [3,4-d]-pirimidina útiles para tratar trastornos respiratorios

Info

Publication number
GT200800256A
GT200800256A GT200800256A GT200800256A GT200800256A GT 200800256 A GT200800256 A GT 200800256A GT 200800256 A GT200800256 A GT 200800256A GT 200800256 A GT200800256 A GT 200800256A GT 200800256 A GT200800256 A GT 200800256A
Authority
GT
Guatemala
Prior art keywords
pirazolo
pirimidine
derivatives
useful
respiratory disorders
Prior art date
Application number
GT200800256A
Other languages
English (en)
Inventor
Bruce Ian
Hayler Judy Fox
Bloomfield Graham Charles
Edwards Lee
Cox Brian
Howsham Catherine
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36687588&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200800256(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of GT200800256A publication Critical patent/GT200800256A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UN COMPUESTO DE LA FÓRMULA I O UNA SAL FARMACÉUTICA ACEPATABLE O UN SOLVATO DEL MISMO DONDE R1-R3 SE DEFINEN EN LA DESCRIPCIÓN, A COMPOSICIONES Y AL USO DE LOS COMPUESTOS EN EL TRATAMIENTO DE ENFERMEDADES QUE SE ALIVIAN MEDIANTE LA INHIBICIÓN DE LA 3-CINASA DE FOSFATIDIL-INOSITOL. T2008
GT200800256A 2006-05-23 2008-11-21 Derivados de pirazolo [3,4-d]-pirimidina útiles para tratar trastornos respiratorios GT200800256A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0610242.0A GB0610242D0 (en) 2006-05-23 2006-05-23 Organic compounds

Publications (1)

Publication Number Publication Date
GT200800256A true GT200800256A (es) 2009-05-28

Family

ID=36687588

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200800256A GT200800256A (es) 2006-05-23 2008-11-21 Derivados de pirazolo [3,4-d]-pirimidina útiles para tratar trastornos respiratorios

Country Status (24)

Country Link
US (5) US20090131457A1 (es)
EP (1) EP2026811A1 (es)
JP (1) JP2009537580A (es)
KR (1) KR101106853B1 (es)
CN (1) CN101443013A (es)
AR (2) AR061057A1 (es)
AU (1) AU2007253615B2 (es)
BR (1) BRPI0712022A2 (es)
CA (1) CA2650661A1 (es)
CL (1) CL2007001455A1 (es)
CR (1) CR10419A (es)
EC (1) ECSP088902A (es)
GB (1) GB0610242D0 (es)
GT (1) GT200800256A (es)
IL (1) IL195017A0 (es)
MA (1) MA30433B1 (es)
MX (1) MX2008014835A (es)
NO (1) NO20084997L (es)
PE (1) PE20080315A1 (es)
RU (1) RU2008150619A (es)
TN (1) TNSN08478A1 (es)
TW (1) TW200806665A (es)
WO (1) WO2007134828A1 (es)
ZA (1) ZA200809097B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520744A (ja) 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 抗炎症性ピラゾロピリミジン
NZ571182A (en) 2006-04-04 2010-09-30 Univ California Pyrazolo[3,4-d]pyrimidines
AU2008278966B2 (en) * 2007-07-26 2012-02-23 Novartis Ag Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
TW200911798A (en) 2007-08-02 2009-03-16 Amgen Inc PI3 kinase modulators and methods of use
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
JP5520831B2 (ja) 2007-12-19 2014-06-11 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
NZ587051A (en) 2008-01-04 2012-12-21 Intellikine Llc Isoquinolinone derivatives, compositions and methods of inhibiting phosphatidyl inositol-3 kinase (pi3 kinase)
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
EP2111861A1 (en) * 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
JP5599783B2 (ja) 2008-05-30 2014-10-01 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
BRPI0915231A2 (pt) * 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
US8220787B2 (en) * 2008-09-19 2012-07-17 Panasonic Corporation Part mounting device
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
ES2570429T3 (es) 2008-10-16 2016-05-18 Univ California Inhibidores de heteroaril quinasa de anillo condensado
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
WO2010114894A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted heterocyclic compounds
CA2760791C (en) 2009-05-07 2017-06-20 Intellikine, Inc. Heterocyclic compounds and uses thereof
EP2488511A1 (en) * 2009-10-02 2012-08-22 Vertex Pharmaceuticals Incorporated Pyrazole inhibitors of phosphatidylinositol 3-kinase
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
WO2011146313A1 (en) * 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
ES2593256T3 (es) 2010-05-21 2016-12-07 Infinity Pharmaceuticals, Inc. Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN103648499B (zh) 2011-01-10 2017-02-15 无限药品股份有限公司 用于制备异喹啉酮的方法及异喹啉酮的固体形式
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
CA2842190A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013032591A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CA2846496C (en) 2011-09-02 2020-07-14 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
IN2014DN01883A (es) 2011-09-14 2015-05-15 Proximagen Ltd
GB201115853D0 (en) 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
CA2850617A1 (en) 2011-10-03 2013-04-11 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013177168A1 (en) 2012-05-22 2013-11-28 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
KR20160027217A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
JP2015532287A (ja) 2012-09-26 2015-11-09 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｉｒｅ１の調節
WO2014062774A1 (en) 2012-10-17 2014-04-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
EP2925752A4 (en) 2012-11-27 2016-06-01 Univ North Carolina PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014153509A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2925944C (en) 2013-10-04 2023-01-10 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP4066834A1 (en) 2014-03-19 2022-10-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015157125A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Therapuetic uses of selected pyrazolopyrimidine compounds with anti-mer tyrosine kinase activity
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CZ308056B6 (cs) * 2015-07-20 2019-11-27 Ustav Experimentalni Botaniky Av Cr V V I 5-Substituované-7-[4-(substituované)benzyl]amino-3-isopropylpyrazolo[4,3-d]pyrimidiny, jejich použití jako antirevmatika, a farmaceutické přípravky
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
DK3442535T3 (da) 2016-04-15 2022-09-05 Cancer Research Tech Ltd Heterocykliske stoffer som as ret-kinase-hæmmere
SG10201911665UA (en) 2016-04-15 2020-01-30 Cancer Research Tech Ltd Heterocyclic compounds as ret kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017223422A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
JOP20180009A1 (ar) * 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR205429A1 (es) * 1971-04-27 1976-05-07 Ciba Geigy Ag Procedimiento para la elaboracion de nuevos derivados de 4-amino - 3-(5-nitro- 2 -furil)-1-metil - 1h - pirazol-(3,4-ol)-pirimidina
AR204665A1 (es) * 1974-05-13 1976-02-20 Lilly Co Eli Procedimiento para preparar compuestos de 3-(5-nitroimidazol-2-il)pirazolo(3,4d)pirimidina
US4044130A (en) * 1974-07-03 1977-08-23 Ciba-Geigy Corporation Compositions for the control of microorganisms
JPS5195094A (en) * 1975-01-31 1976-08-20 * ***** ****so*shi***** *o*u****** ********ne***u**** *** *** ****ne*** *************te***ku**
GB0013674D0 (en) * 1999-06-08 2000-07-26 Lorantis Ltd Therapeutic use
SK3812002A3 (en) * 1999-09-17 2003-09-11 Abbott Gmbh & Co Kg Pyrazolopyrimidines as therapeutic agents
WO2001081346A2 (en) * 2000-04-25 2001-11-01 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
ES2309206T3 (es) * 2001-10-02 2008-12-16 Smithkline Beecham Corporation Compuestos quimicos.
US20030180924A1 (en) * 2002-03-22 2003-09-25 Desimone Robert W. Formulation of certain pyrazolo [3,4,-d] pyrimidines as kinase modulators
US7429596B2 (en) * 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
JP2007520559A (ja) * 2004-02-03 2007-07-26 アボット・ラボラトリーズ 治療薬としてのアミノベンゾオキサゾール類
JP2008520744A (ja) * 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 抗炎症性ピラゾロピリミジン
JP2009531443A (ja) * 2006-03-29 2009-09-03 フォールドアールエックス ファーマシューティカルズ インコーポレーティッド α−シヌクレイン毒性の抑制

Also Published As

Publication number Publication date
NO20084997L (no) 2008-12-22
CN101443013A (zh) 2009-05-27
AR110051A2 (es) 2019-02-20
EP2026811A1 (en) 2009-02-25
AU2007253615B2 (en) 2011-06-23
US8901134B2 (en) 2014-12-02
CR10419A (es) 2011-07-19
KR101106853B1 (ko) 2012-01-19
IL195017A0 (en) 2009-08-03
CL2007001455A1 (es) 2008-05-16
US20160303132A1 (en) 2016-10-20
KR20090008392A (ko) 2009-01-21
GB0610242D0 (en) 2006-07-05
PE20080315A1 (es) 2008-06-11
BRPI0712022A2 (pt) 2011-12-27
TW200806665A (en) 2008-02-01
US20140235632A1 (en) 2014-08-21
US20090131457A1 (en) 2009-05-21
MX2008014835A (es) 2008-12-01
AR061057A1 (es) 2008-07-30
MA30433B1 (fr) 2009-05-04
ECSP088902A (es) 2008-12-30
CA2650661A1 (en) 2007-11-29
JP2009537580A (ja) 2009-10-29
ZA200809097B (en) 2009-11-25
US20140051698A1 (en) 2014-02-20
RU2008150619A (ru) 2010-06-27
WO2007134828A1 (en) 2007-11-29
AU2007253615A1 (en) 2007-11-29
TNSN08478A1 (en) 2010-04-14
US20180125849A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
GT200800256A (es) Derivados de pirazolo [3,4-d]-pirimidina útiles para tratar trastornos respiratorios
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
CR20140392A (es) Dihidropirazolonas sustituidas
DOP2011000218A (es) Derivados de sulfonamida
SV2011003802A (es) Derivados de triazol utiles para el tratamiento de enfermedades
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
AR062394A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis
SV2011003939A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
UY31228A1 (es) Ariloxazoles sustituidos y su uso
BRPI0714908B8 (pt) derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende
BR112012021364A2 (pt) "compostos cicloalquila contendo tienopirimidinas e composições farmacêuticas".
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
PA8627001A1 (es) Compuestos para el tratamiento de enfermedades
CR10356A (es) Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
BR112012013252A2 (pt) composição farmacêutica tópica, preservativo, composto, e, uso do mesmo
BRPI0706992C1 (pt) composto de fórmula (i) e formulação farmacêutica
CR20110318A (es) Compuestos, composición farmacéutica y métodos para utilizarse en el tratamiento de trastornos metabólicos
UY31990A (es) Nuevos derivados
BRPI0715698B8 (pt) produto, composição farmacêutica que o contém e uso de composto